

# Meningococcal Vaccines – Provider Version



This document lays out the recommended adolescent vaccinations for Meningococcal disease in the United States. Each of these have been approved by the FDA for administration within the United States. Brand names, manufacturers, and recommendations for each vaccination is provided below.

Vaccination Name	Formula	Manufacturer	Serogroups Covered	Standing Recommendations	Age Range & Number of Doses	Vaccination Package Inserts
<b>Routinely Recommended: Quadrivalent Meningococcal Conjugate Vaccines</b>						
<b>Menactra</b>	MenACWY-D (also known as an MCV4)	Sanofi Pasteur Inc.	A,C,W,Y	<p>Recommended for ages:</p> <ul style="list-style-type: none"> <li>• 11-12 years old, first dose (out of 2); Booster dose before 16<sup>th</sup> birthday</li> <li>• 13-18 years old, first dose (out of 2) if not previously vaccinated at ages 11-12; Booster dose before 16<sup>th</sup> birthday</li> <li>• Age 19-21; not typically recommended but may be given a catch up</li> </ul>	<ul style="list-style-type: none"> <li>• Ages 2 through 55 years old as a single dose series*</li> <li>• Children 9 months through 23 months as a 2-dose series 3 months apart.</li> </ul>	<a href="http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf">http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf</a>
<b>Menveo</b>	MenACWY-CRM (also known as an MCV4)	GlaxoSmithKline	A,C,W,Y	<p>Recommended for ages:</p> <ul style="list-style-type: none"> <li>• 11-12 years old, first dose (out of 2); Booster dose before 16<sup>th</sup> birthday</li> <li>• 13-18 years old, first dose (out of 2) if not previously vaccinated; Booster dose before 16<sup>th</sup> birthday</li> <li>• Age 19-21; not typically recommended but may be given a catch up</li> </ul>	<ul style="list-style-type: none"> <li>• In infants 2 months old, a 4 dose series is administered at 2, 4, 6, and 12 months of age.</li> <li>• In children 7 to 23 months old, a 2-dose series is administered, with the 2<sup>nd</sup> dose administered at 2 years old and at least 3 months after the first.</li> <li>• In children 2-10 years of age, a 2-dose series is administered with the second dose 2 months after the 1<sup>st</sup>.</li> <li>• Ages 11 through 55 years old as a single dose series*</li> </ul>	<a href="http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf">http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf</a>

Vaccination Name	Formula	Manufacturer	Serogroups Covered	Standing Recommendations	Age Range & Number of Doses	Vaccination Package Inserts
<b>Recommended for High Risk: Meningococcal Polysaccharide &amp; Meningococcal Conjugate Vaccines</b>						
<b>Menomune</b>	MPSV4 – polysaccharide vaccination	Sanofi Pasteur Inc.	A,C,W,Y	Only vaccine licensed and available for adults ≥56 years old.	Approved for all ages ≥2 years old as a single dose series	<a href="http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308370.pdf">http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308370.pdf</a>
<b>MenHibrix</b>	HibMenCY-TT	GlaxoSmithKline	C & Y	Recommended for children who: <ul style="list-style-type: none"> <li>• Have persistent complement deficiencies</li> <li>• Have functional or anatomic asplenia</li> <li>• Are at risk during a community outbreak attributable to a vaccine serogroup</li> </ul>	Ages 2 months through 18 months as a 4-dose series	<a href="http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308577.pdf">http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308577.pdf</a>
<b>Serogroup B Meningococcal (MenB) Vaccines</b>						
<b>Trumenba</b>	MenB-FHbp	Wyeth Pharmaceuticals	B	May be administered to adolescents 16-23 years old; the preferred age for MenB vaccination is 16-18 years old The second and third doses are administered at 2 and 6 months, respectively, after the first dose	Ages 10 through 25 years old as a 3-dose series	<a href="http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf">http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf</a>
<b>Bexsero</b>	MenB-4C	GlaxoSmithKline	B	May be administered to adolescents 16-23 years old; the preferred age for MenB vaccination is 16-18 years old The second dose is administered at least 1 month after the first.	Ages 10 through 25 years old as a 2-dose series	<a href="http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf">http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf</a>

\*note: a booster dose may be given to individuals 15 through 55 years old who are at a continued risk

### Resources

- [http://www.immunize.org/cata\\_d/p4210.pdf](http://www.immunize.org/cata_d/p4210.pdf) - Meningococcal Q&A
- <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308370.pdf> - package insert for Menomune
- <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308577.pdf> - package insert for MenHibrix
- <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf> - package insert for Menactra
- <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf> - package insert for Menveo
- <http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf> - MMWR - Meningococcal Immunization Practices (ACWY)
- <http://www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6543a3.pdf> - HIV positive persons
- <http://www.cdc.gov/mmwr/pdf/wk/mm6441.pdf#page=11> - Men B information/recommendations (page 11 start)
- <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf> - package insert for Trumenba
- <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf> - package insert for Bexsero